About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT01176968

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.

Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.•75 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.

Exclusion Criteria

•Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.
•Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.
•The subject has uncontrolled hypotension (SBP\<90mmHg).
•Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.

Related studies

RECRUITINGPhase 4

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

NCT06710184 · NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Acute Myocardial Infarction (AMI)

RECRUITINGPhase 3

Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial

NCT07478003 · STEMI - ST Elevation Myocardial Infarction

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

NCT07142265 · Myocardial Infarction

RECRUITINGPhase 2

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131 · Acute Myocardial Infarction Type 1

Artificial Intelligence Scalable Solution for ST Myocardial Infarction

NCT06939738 · Acute Myocardial Infarction (AMI)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 22, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment1,012

Start dateSep 2010

Last updatedDec 22, 2020

Condition

Myocardial Infarction

Locations shown

University of Alberta Hospital

Edmonton, Alberta

Walter C Mackenzie Health Sciences Centre (WCM)

Edmonton, Alberta

Diamond Health Care Centre (DHCC)

Vancouver, British Columbia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions